Share >  
Share
Share on Tumblr

Pharmasianews.com

News »

   latest by relevance
Cipla's price cut is strategic move: Expert
May 04, 2012 at 13:01 | Source: CNBC-TV18
Cipla's move to slash price of its cancer drug by almost 75% is a strong one, this is not only a humanitarian move, but is a strategic play as well, Vikas Dandekar of Pharmasianews.com told CNBC-TV18.
Pfizer sees good value in deal with Biocon: Pharmasianews
Oct 18, 2010 at 19:14 | Source: CNBC-TV18
Biocon and Pfizer have entered into a global commercialisation agreement. Pfizer will make an upfront payment of USD 200 million for the licensing deal for Biocons biosimilar insulin portfolio diabetics treatment. In an interview with CNBC-TV18, Vikas Dandekar of pharmasianews.com gave his perspective on the deal.
Pharma M&A: Should govt fret over foreign takeovers?
Aug 25, 2010 at 22:25 | Source: CNBC-TV18
Pharmaceutical major Ranbaxy may offer to pay a one-time penalty to the US Food and Drug Administration (FDA), learns CNBC-TV18 quoting sources. In an interview with CNBC-TV18's Executive Editor Shereen Bhan and News Editor Harsha Subramaniam, Vikas Dandekar of Pharmasianews.com gave his perspective on the issue.
Growth formula: Experts analyse the Abbott-Piramal deal
May 21, 2010 at 20:56 | Source: CNBC-TV18
Abbott laboratories will buy Piramal Healthcare's domestic formulations business for a whopping USD 3.7 billion. In an interview with CNBC-TV18, Sujay Shetty, Leader - Pharma (India), PwC and Vikas Dandekar of Pharmasianews.com, gave their perspectives on the deal.
Ranbaxys US unit Ohm Labs gets FDA warning
Dec 24, 2009 at 20:30 | Source: CNBC-TV18
Ranbaxy is in the US FDA's cross hairs yet again. The pharma major's wholly-owned unit Ohm Laboratories has received a warning letter relating to violations of good manufacturing practices.
Hospira to acquire Orchid's injectibles biz for $400m
Dec 16, 2009 at 09:08 | Source: CNBC-TV18
US-based pharmaceutical major Hospira has gained a footprint in India reports CNBC-TV18's Sajeet Manghat.

Videos »
Cipla's price cut is strategic move: Expert
Pfizer sees good value in deal with Biocon: Pharmasianews
Pharma M&A: Should govt fret over foreign takeovers?
Growth formula: Experts analyse the Abbott-Piramal deal
Ranbaxys US unit Ohm Labs gets FDA warning
more »

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window